 Criteria for inclusion were randomized, placebocontrolled clinical trials on Sipuleucel-T, patients with any types of prostate cancer, patients receiving three infusions, 36 months follow-up, the availability of outcomes data for adverse events.
 The primary outcome was the relative risk of total number of adverse events. Secondary outcomes examined the relative risk of seventeen specified adverse events.
 To ensure the quality of the studies, two investigators selected studies independently and assessed the quality of studies using the Jadad scale. We excluded all studies with a Jadad score of 3 or less.
 Point estimates of relative risk with a 95% confidence interval were generated. The decision to use a fixed-effects or random-effects model was based on the evaluation of heterogeneity. If there was statistical significance in the evaluation of heterogeneity, we used the random-effects model. Otherwise, we used the fixed-effects model.
Background
 Prostate cancer is the most common cancer in men.
 The estimated number of new cases of prostate cancer in the United States in 2015 is 220,800 and the estimated number of deaths due to prostate cancer is 27,540.
 Sipuleucel-T is the first therapeutic cancer vaccine approved by U.S. Food and Drug Administration in 2010.
 Evidence shows that Sipuleucel-T could prolong the survival and reduce death in patients with prostate cancer by eliciting T-cell immunity against prostatic acid phosphatase.
 Previous studies have indicated that Sipuleucel-T was well tolerated. But in some clinical trails, an increased incidence of adverse events was reported after treatment of Sipuleucel-T.
 To our knowledge, no long-term, large sample size, real-world observational study on safety of Sipuleucel-T has been conducted.
Objective
 The aim of this study was to evaluate the safety of Sipuleucel-T in patients with prostate cancer by conducting a meta-analysis based on current evidence.
Results
Three clinical trials encompassing 814 patients were included. The results of the study selection are presented in Figure 1 and the characteristics of studies included are listed in the Table 1 .
The overall adverse events relative risk (RR) was 1.02 with a 95% confidence interval from 0.991 to 1.050 and a p-value of 0.911. The forest plot is presented in Figure 2 .
Significant differences were detected between Sipuleucel-T and placebo on six specified adverse events, which were chills, headache, influenza-like illness, myalgia, vomiting and pyrexia. The relative risks are listed in the table 2. 
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Conclusions
 Sipuleucel-T significantly increased the risk of selected adverse events in patients with prostate cancer. Although most of these adverse events were considered to have association with cytokine release, patients and providers should consider the potential risk of treatment with Sipuleucel-T.
Limitations
 The adverse events may be different for patients with a different disease state.  We evaluated only all grade adverse events.
Serious adverse events will be evaluated in a future study. 
